NICE backs NHS use of Takeda’s Adcetris for rare blood cancerTakeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form Share XNICE backs NHS use of Takeda’s Adcetris for rare blood cancerhttps://pharmaphorum.com/news/nice-backs-nhs-use-of-takedas-adcetris-for-rare-blood-cancer/
Takeda to make $200m loss after Novartis’ dry-eye drug hits trouble in EuropeNovartis’ decision to withdraw a European filing for its dry-eye drug Xiidra is to have a knock-on effect on Takeda, causing Share XTakeda to make $200m loss after Novartis’ dry-eye drug hits trouble in Europehttps://pharmaphorum.com/news/takeda-to-make-200m-loss-after-novartis-dry-eye-drug-hits-trouble-in-europe/
After Celgene deal, BMS shoots up pharma market cap rankingsBristol-Myers Squibb $74 billion takeover of Celgene saw it shoot up the list of top 20 pharma companies Share XAfter Celgene deal, BMS shoots up pharma market cap rankingshttps://pharmaphorum.com/news/after-celgene-deal-bms-shoots-up-pharma-market-cap-rankings/
Celltrion buys drug portfolio from Takeda, ventures into chronic diseasesSouth Korea’s Celltrion has made its first major acquisition, buying a portfolio of drugs including diabetes and hypertension drugs from Share XCelltrion buys drug portfolio from Takeda, ventures into chronic diseaseshttps://pharmaphorum.com/news/celltrion-ventures-into-chronic-diseases-with-takeda-portfolio-buy/
Takeda posts surprise profit a year after Shire mega-mergerJapan’s Takeda has posted a surprise profit after its $59 billion merger with Shire just over a year Share XTakeda posts surprise profit a year after Shire mega-mergerhttps://pharmaphorum.com/news/takeda-posts-surprise-profit-a-year-after-shire-mega-merger/
Takeda to sell European OTC business to cut debtsJapan’s Takeda has said it would sell up to $670 million of over-the-counter (OTC) drug operations in Europe Share XTakeda to sell European OTC business to cut debtshttps://pharmaphorum.com/news/takeda-to-sell-european-otc-business-to-cut-debts/
Breadth versus depth in R&D managementTakeda’s Georgia Keresty is one of the only chief operating officers (COOs) for R&D in the industry. She Share XBreadth versus depth in R&D managementhttps://deep-dive.pharmaphorum.com/magazine/research-and-development-disruption-2020/breadth-versus-depth-in-r-and-d-management/
Plasma firms join forces on “unbranded” coronavirus treatmentA group of companies that specialise in plasma-derived drugs will pool their resources to try to develop a Share XPlasma firms join forces on “unbranded” coronavirus treatmenthttps://pharmaphorum.com/news/plasma-firms-join-forces-on-unbranded-coronavirus-treatment/
Takeda signs $882m rare disease alliance with Oxford biotech EvoxEvox Therapeutics is the second UK biotech to sign a big deal with a pharma giant this week, Share XTakeda signs $882m rare disease alliance with Oxford biotech Evoxhttps://pharmaphorum.com/news/takeda-signs-882m-rare-disease-alliance-with-oxford-biotech-evox/
